Beck Mack & Oliver LLC lifted its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 75.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,148 shares of the biopharmaceutical company’s stock after acquiring an additional 10,800 shares during the period. Beck Mack & Oliver LLC’s holdings in Bristol-Myers Squibb were worth $1,603,000 as of its most recent SEC filing.
Several other hedge funds also recently made changes to their positions in the company. Tradewinds Capital Management LLC grew its position in Bristol-Myers Squibb by 34.6% in the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 500 shares in the last quarter. Atlantic Trust LLC acquired a new stake in Bristol-Myers Squibb in the second quarter valued at approximately $111,000. American National Bank grew its position in Bristol-Myers Squibb by 11.7% in the second quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock valued at $119,000 after acquiring an additional 225 shares in the last quarter. Blue Chip Partners Inc. grew its position in Bristol-Myers Squibb by 0.7% in the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after acquiring an additional 15 shares in the last quarter. Finally, Heritage Trust Co acquired a new stake in Bristol-Myers Squibb in the first quarter valued at approximately $123,000. Institutional investors and hedge funds own 69.66% of the company’s stock.
Bristol-Myers Squibb Co (NYSE:BMY) opened at $61.28 on Friday. The stock has a market capitalization of $100,951.66, a PE ratio of 24.13, a P/E/G ratio of 2.34 and a beta of 1.18. Bristol-Myers Squibb Co has a fifty-two week low of $46.01 and a fifty-two week high of $66.10. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47.
The business also recently declared a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be paid a $0.40 dividend. The ex-dividend date is Thursday, January 4th. This represents a $1.60 dividend on an annualized basis and a yield of 2.61%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 61.42%.
In related news, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the transaction, the executive vice president now owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of Bristol-Myers Squibb stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total value of $335,172.00. Following the completion of the transaction, the executive vice president now directly owns 9,251 shares in the company, valued at approximately $585,033.24. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.
Several brokerages recently issued reports on BMY. Barclays raised their price objective on Bristol-Myers Squibb from $58.00 to $65.00 and gave the stock an “equal weight” rating in a research note on Friday, October 13th. Jefferies Group cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 price objective on the stock. in a research note on Monday, October 16th. BMO Capital Markets set a $49.00 price objective on Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Thursday, October 12th. Leerink Swann raised their target price on Bristol-Myers Squibb from $61.00 to $72.00 and gave the company an “outperform” rating in a research note on Monday, October 23rd. Finally, Citigroup raised their target price on Bristol-Myers Squibb to $72.00 and gave the company a “buy” rating in a research note on Wednesday, October 18th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $64.42.
ILLEGAL ACTIVITY WARNING: This report was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.com-unik.info/2017/12/30/bristol-myers-squibb-co-bmy-stake-lifted-by-beck-mack-oliver-llc.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
What are top analysts saying about Bristol-Myers Squibb? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bristol-Myers Squibb and related companies.